Screener
Avalo Therapeutics AVTX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's return on equity?
- Avalo Therapeutics (AVTX) reported return on equity of -36.3% in Q2 2026.
- What is the long-term trend for Avalo Therapeutics's return on equity?
- Over 3 years (2020 to 2025), Avalo Therapeutics's return on equity has grown at a -36.2% compound annual growth rate (CAGR), from -278.8% to -72.4%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Avalo Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude